<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003624</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066705</org_study_id>
    <secondary_id>GOG-9805</secondary_id>
    <nct_id>NCT00003624</nct_id>
  </id_info>
  <brief_title>Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer</brief_title>
  <official_title>A Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells
      from the side effects of chemotherapy.

      PURPOSE: Phase II trial to study the effectiveness of amifostine in reducing the risk of side
      effects caused by cisplatin and paclitaxel in treating women who have ovarian, peritoneal,
      cervical, fallopian tube, uterine, or endometrial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of amifostine in reducing significant peripheral
      neuropathy in women with ovarian, peritoneal, cervical, fallopian tube, uterine, or
      endometrial cancer treated with cisplatin and paclitaxel. II. Determine the proportion of
      patients on this regimen who experience significant peripheral neuropathy 3 months after
      completing chemotherapy. III. Assess the overall toxicity of this regimen in these patients.

      OUTLINE: Patients receive paclitaxel IV over 3 hours, amifostine IV over 10 minutes, and
      cisplatin IV over 90 minutes. Treatment repeats every 3 weeks for 6 courses in the absence of
      disease progression or unacceptable toxicity. Neurotoxicity is assessed and vibration
      perception threshold testing is performed prior to each course of chemotherapy and at 3
      months following the last treatment. Patients are followed every 3 months for 2 years, then
      every 6 months for 3 years, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 29-59 patients will be accrued for this study within 18-36
      months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 1998</start_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Neurotoxicity</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Ovarian, primary peritoneal, cervical, or fallopian tube
        carcinoma, uterine sarcoma, or endometrial adenocarcinoma for which the proposed treatment
        is cisplatin plus paclitaxel Must be ineligible for a higher priority GOG protocol

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-3 Life expectancy:
        Not specified Hematopoietic: WBC at least 3,000/mm3 Granulocyte count at least 1,500/mm3
        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper
        limit of normal (ULN) AST and alkaline phosphatase no greater than 3 times ULN Renal:
        Creatinine no greater than 2.0 mg/dL Cardiovascular: No hypertension for which medication
        cannot be discontinued for 24 hours through the day of each chemotherapy treatment Other:
        No history of neuropathy (e.g., diabetic neuropathy) No significant infection Prior
        malignancy allowed if disease free for at least 12 months No physical disabilities
        precluding vibration perception threshold testing of the upper and lower extremity (e.g.,
        amputation, paraplegia)

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy for ovarian, primary peritoneal, or fallopian tube carcinoma, uterine sarcoma,
        or endometrial adenocarcinoma Endocrine therapy: Not specified Radiotherapy: No prior
        radiotherapy except for cervical carcinoma Surgery: Not specified
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H. Moore, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University Melvin and Bren Simon Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincent T. Lombardi Cancer Research Center, Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE; Gynecologic Oncology Group. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol. 2003 Nov 15;21(22):4207-13.</citation>
    <PMID>14615449</PMID>
  </results_reference>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2004</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <keyword>stage I cervical cancer</keyword>
  <keyword>stage II cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IV cervical cancer</keyword>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage I endometrial carcinoma</keyword>
  <keyword>stage II endometrial carcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>endometrial adenocarcinoma</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <keyword>stage I uterine sarcoma</keyword>
  <keyword>stage II uterine sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>neurotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

